Ahmed Alenezi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ahmed Alenezi has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Khaled Soliman
Medical Physics Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
9 shared publications Salman Altimyat
3 shared publicationsAbdullah Alrushoud
2 shared publicationsTurki Alruwaili
2 shared publicationsAbdelmoneim Sulieman
1 shared publication- Abdullah Alrushoud1 shared publication
Latest Publications
- 21 June 2022
- Published by Elsevier in Radiation Physics and Chemistry
- Vol. 200
Effective radiation doses in neck computed tomography scans
- 21 June 2022
- Published by Elsevier in Radiation Physics and Chemistry
- Vol. 200
Effective radiation doses in neck computed tomography scans
- Open Access
- 15 June 2022
- Published by IntechOpen
Recent Advances in Biodistribution, Preclinical and Clinical Applications of Radiolabelled Iodine
Adequate understanding of radiopharmaceutical distribution in the body of the patient has both spatial and temporal characteristics and they are the key factor to consider when planning successful radio pharmaceutical therapy, because they are an integral part of the radiation dosimetry calculations of any proposed personalized treatment. In this chapter we will focus on radioiodine therapy for thyroid cancer patients since it is a widely known practice in clinical oncology. Factors affecting the radioiodine organs’ distribution will be examined in sufficient details using the available published research in the scientific literature. The literature will be reviewed extensively and summarized in this chapter. Another aim is to provide the medical practitioners with a quick reference guide to this clinically important area of expertise; often mastered by medical physicists with background in radiation physics, mathematics and medical imaging analysis. This chapter will cover recent advances in the area of radioiodine biodistribution modeling with applications in preclinical and clinical studies.
- 15 June 2022
- Published by IntechOpen
Open AccessRecent Advances in Biodistribution, Preclinical and Clinical Applications of Radiolabelled Iodine
Adequate understanding of radiopharmaceutical distribution in the body of the patient has both spatial and temporal characteristics and they are the key factor to consider when planning successful radio pharmaceutical therapy, because they are an integral part of the radiation dosimetry calculations of any proposed personalized treatment. In this chapter we will focus on radioiodine therapy for thyroid cancer patients since it is a widely known practice in clinical oncology. Factors affecting the radioiodine organs’ distribution will be examined in sufficient details using the available published research in the scientific literature. The literature will be reviewed extensively and summarized in this chapter. Another aim is to provide the medical practitioners with a quick reference guide to this clinically important area of expertise; often mastered by medical physicists with background in radiation physics, mathematics and medical imaging analysis. This chapter will cover recent advances in the area of radioiodine biodistribution modeling with applications in preclinical and clinical studies.
- 1 May 2020
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 41 (8) , 830-835
Logistic regression analysis of repeated radioiodine therapy treatments for papillary thyroid carcinoma patients
Purpose Radioiodine ablation treatment (RAT) is administered to papillary thyroid carcinoma patients post thyroidectomy. Multivariable logistic regression analysis can be applied to predict treatment failure. In this study, we propose a logistic regression model (LRM) to estimate the probability of repeating the treatment more than one time. Materials and methods A retrospective review of the last 5 years of RAT data revealed that 30 patients had received the RAT more than one time. Various factors including age, sex, pretreatment serum thyroglobulin (Tg), thyroid-stimulating hormone (TSH) and administered activity were analyzed to predict RAT failure and therefore the necessity to repeat the treatment by administering additional doses of radioiodine. Results The administered activity, the patient age, the presence of distant lymph nodes on the whole-body radioiodine scan (WBS) and the level of Tg before the treatment were found to be the predictive variables. The following LRM is proposed: Y = 7.8295 − 0.0012 [Activity in (MBq) − 0.0541 (Age) − 34.3 (Lymph Nodes) − 0.0042 (Tg)]. The prediction accuracy of the LRM was assessed using receiver operating characteristic (ROC) curve by calculating the area under the curve (AUC). We found the AUC = 0.8972. Conclusion Patients who are older in age, who receive higher administered radioiodine activity, have higher serum thyroglobulin levels and have lymph node uptake reported in their post-ablation WBS are more likely to have unsuccessful treatment outcome and will repeat the treatment. This LRM could help in adjusting RAT options in order to reduce the repeat rate.
- 1 May 2020
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 41 (8) , 830-835
Logistic regression analysis of repeated radioiodine therapy treatments for papillary thyroid carcinoma patients
Purpose Radioiodine ablation treatment (RAT) is administered to papillary thyroid carcinoma patients post thyroidectomy. Multivariable logistic regression analysis can be applied to predict treatment failure. In this study, we propose a logistic regression model (LRM) to estimate the probability of repeating the treatment more than one time. Materials and methods A retrospective review of the last 5 years of RAT data revealed that 30 patients had received the RAT more than one time. Various factors including age, sex, pretreatment serum thyroglobulin (Tg), thyroid-stimulating hormone (TSH) and administered activity were analyzed to predict RAT failure and therefore the necessity to repeat the treatment by administering additional doses of radioiodine. Results The administered activity, the patient age, the presence of distant lymph nodes on the whole-body radioiodine scan (WBS) and the level of Tg before the treatment were found to be the predictive variables. The following LRM is proposed: Y = 7.8295 − 0.0012 [Activity in (MBq) − 0.0541 (Age) − 34.3 (Lymph Nodes) − 0.0042 (Tg)]. The prediction accuracy of the LRM was assessed using receiver operating characteristic (ROC) curve by calculating the area under the curve (AUC). We found the AUC = 0.8972. Conclusion Patients who are older in age, who receive higher administered radioiodine activity, have higher serum thyroglobulin levels and have lymph node uptake reported in their post-ablation WBS are more likely to have unsuccessful treatment outcome and will repeat the treatment. This LRM could help in adjusting RAT options in order to reduce the repeat rate.
- Open Access
- 24 July 2019
- Published by IntechOpen
Applied Radiation Protection Physics
Nuclear medicine is an area where both patients and occupational radiation doses are among the highest in diagnostic imaging modalities today. Therefore, a good understanding and proper application of radiation protection principles are of great importance. Such understanding will allow optimization of practice that will be translated into cost savings for health care administrations worldwide. This chapter will tackle: radiation protection in the routine practice of both diagnostic and therapy applications in nuclear medicine including PET, diagnostic facility design, safety aspects of the common radionuclides used in clinics, the safety of the pregnant and breast feeding patients, radiation effect of exposure to ionizing radiation, and risk estimates. The chapter will discuss the operational radiation safety program requirements applied to Conventional Nuclear Medicine using Gamma Cameras, SPECT/CT, PET/CT, and Radioiodine therapy facilities. The chapter will serve as a quick reference and as a guide to access more detailed information resources available in the scientific literature.
- 24 July 2019
- Published by IntechOpen
Open AccessApplied Radiation Protection Physics
Nuclear medicine is an area where both patients and occupational radiation doses are among the highest in diagnostic imaging modalities today. Therefore, a good understanding and proper application of radiation protection principles are of great importance. Such understanding will allow optimization of practice that will be translated into cost savings for health care administrations worldwide. This chapter will tackle: radiation protection in the routine practice of both diagnostic and therapy applications in nuclear medicine including PET, diagnostic facility design, safety aspects of the common radionuclides used in clinics, the safety of the pregnant and breast feeding patients, radiation effect of exposure to ionizing radiation, and risk estimates. The chapter will discuss the operational radiation safety program requirements applied to Conventional Nuclear Medicine using Gamma Cameras, SPECT/CT, PET/CT, and Radioiodine therapy facilities. The chapter will serve as a quick reference and as a guide to access more detailed information resources available in the scientific literature.
- Open Access
- 28 December 2018
- Published by ACT Publishing Group in International Journal of Radiology
- Vol. 5 (1) , 157-160
Five Years Review of Occupational Dosimetry Program at A Tertiary Care Hospital and Comparison With UNSCEAR 2008 Report
Five Years Review of Occupational Dosimetry Program at A Tertiary Care Hospital and Comparison With UNSCEAR 2008 Report
- 28 December 2018
- Published by ACT Publishing Group in International Journal of Radiology
- Vol. 5 (1) , 157-160
Open AccessFive Years Review of Occupational Dosimetry Program at A Tertiary Care Hospital and Comparison With UNSCEAR 2008 Report
Five Years Review of Occupational Dosimetry Program at A Tertiary Care Hospital and Comparison With UNSCEAR 2008 Report
- 1 September 2016
- Published by Elsevier in Physica Medica
- Vol. 32, 285
Measurements of dose rate constant corrected for self attenuation from patients injected with 18F (FDG)
- 1 September 2016
- Published by Elsevier in Physica Medica
- Vol. 32, 285
Measurements of dose rate constant corrected for self attenuation from patients injected with 18F (FDG)
- 1 September 2016
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 37 (9) , 992-996
Variability in the amount of fluorine-18 fluorodeoxyglucose excreted in urine measured from oncology patients during PET/computed tomography imaging
The objectives of this work were to estimate the amount of fluorine-18 fluorodeoxyglucose (F-FDG) excreted (AFE) in the patient urine during the uptake phase as percentage of the injected activity and to examine the effect of blood glucose levels (BGL) on the excreted amount and whether it varies among men and women using statistical analysis methods. Radiation dose rates were measured at 1 m from 50 patients, 24 men and 26 women, before and after the first void using a calibrated ionization chamber. The F-FDG was injected in the patients using a calibrated automatic dose injection system. Statistical analysis using hypothesis testing was carried out. Patients with BGL above 5 mmol/l had a higher AFE of 12.3% in comparison with 8.3% of the patients with BGL below 5 mmol/l. A statistically nonsignificant correlation (r=0.183, P<0.249) between AFE and BGL was found; a nonsignificant difference was found in the AFE measured among the male and female patients. The AFE measured was 12±6%, with a range of (2-30%). There was a wide variation in the first void time of 39±8 min, with a range of (17-68) min. A simple noninvasive measurement method is presented that enabled the estimation of the amount of F-FDG excreted from the patient during voiding. Statistical analysis concluded that the amount of F-FDG excreted does not depend on sex, but is perhaps influenced by BGL.
- 1 September 2016
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 37 (9) , 992-996
Variability in the amount of fluorine-18 fluorodeoxyglucose excreted in urine measured from oncology patients during PET/computed tomography imaging
The objectives of this work were to estimate the amount of fluorine-18 fluorodeoxyglucose (F-FDG) excreted (AFE) in the patient urine during the uptake phase as percentage of the injected activity and to examine the effect of blood glucose levels (BGL) on the excreted amount and whether it varies among men and women using statistical analysis methods. Radiation dose rates were measured at 1 m from 50 patients, 24 men and 26 women, before and after the first void using a calibrated ionization chamber. The F-FDG was injected in the patients using a calibrated automatic dose injection system. Statistical analysis using hypothesis testing was carried out. Patients with BGL above 5 mmol/l had a higher AFE of 12.3% in comparison with 8.3% of the patients with BGL below 5 mmol/l. A statistically nonsignificant correlation (r=0.183, P<0.249) between AFE and BGL was found; a nonsignificant difference was found in the AFE measured among the male and female patients. The AFE measured was 12±6%, with a range of (2-30%). There was a wide variation in the first void time of 39±8 min, with a range of (17-68) min. A simple noninvasive measurement method is presented that enabled the estimation of the amount of F-FDG excreted from the patient during voiding. Statistical analysis concluded that the amount of F-FDG excreted does not depend on sex, but is perhaps influenced by BGL.
- 9 April 2015
- Published by Oxford University Press (OUP) in Radiation Protection Dosimetry
- Vol. 165 (1) , 448-451
Measurement and analysis of patient attenuation correction factor during radioiodine therapy
The calculated dose rate from the radioiodine therapy patient should normally include a factor accounting for the attenuation and scatter of patient body tissues. The attenuation factor is currently neglected, and not applied in operational radiation protection. Realistic estimation of radiation dose rate levels from radioiodine therapy patients when properly performed will reduce operational cost and optimise institutional radiation protection practice. In this work, the existence of a patient body tissue attenuation factor is verified by comparing the dose rates measured from the radioiodine capsules immediately before administration with those measured from the patient immediately after administration. The correlation between the factors suspected to influence the patient body tissue attenuation and the measured dose rates from the patient normalised per unit activity is statistically analysed. The calculated attenuation correction factor based on authors’ measurements was (0.55±0.17). The measured dose rate per unit of radioactivity from the patient showed a negative correlation with their body mass index.
- 9 April 2015
- Published by Oxford University Press (OUP) in Radiation Protection Dosimetry
- Vol. 165 (1) , 448-451
Measurement and analysis of patient attenuation correction factor during radioiodine therapy
The calculated dose rate from the radioiodine therapy patient should normally include a factor accounting for the attenuation and scatter of patient body tissues. The attenuation factor is currently neglected, and not applied in operational radiation protection. Realistic estimation of radiation dose rate levels from radioiodine therapy patients when properly performed will reduce operational cost and optimise institutional radiation protection practice. In this work, the existence of a patient body tissue attenuation factor is verified by comparing the dose rates measured from the radioiodine capsules immediately before administration with those measured from the patient immediately after administration. The correlation between the factors suspected to influence the patient body tissue attenuation and the measured dose rates from the patient normalised per unit activity is statistically analysed. The calculated attenuation correction factor based on authors’ measurements was (0.55±0.17). The measured dose rate per unit of radioactivity from the patient showed a negative correlation with their body mass index.
- 1 February 2015
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 36 (2) , 125-128
Estimation of patient attenuation factor for iodine-131 based on direct dose rate measurements from radioiodine therapy patients
The aim of the study was to measure the actual dose at 1 m from the patients per unit activity with the aim of providing a more accurate prediction of the dose levels around radioiodine patients in the hospital, as well as to compare our results with the literature. In this work the demonstration of a patient body tissue attenuation factor is verified by comparing the dose rates measured from the patients with those measured from the unshielded radioiodine capsules immediately after administration of the radioactivity. The normalized dose rate per unit activity is therefore proposed as an operational quantity that can be used to predict exposure rates to staff and patients’ relatives. The average dose rate measured from our patient per unit activity was 38.4±11.8 μSv/h/GBq. The calculated attenuation correction factor based on our measurements was 0.55±0.17. The calculated dose rate from a radioiodine therapy patient should normally include a factor accounting for patient body tissue attenuation and scatter. The attenuation factor is currently neglected and not applied in operational radiation protection. Realistic estimation of radiation dose levels from radioiodine therapy patients when properly performed will reduce the operational cost and optimize institutional radiation protection practice. It is recommended to include patient attenuation factors in risk assessment exercises – in particular, when accurate estimates of total effective doses to exposed individuals are required when direct measurements are not possible. The information provided about patient attenuation might benefit radiation protection specialists and regulators.
- 1 February 2015
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 36 (2) , 125-128
Estimation of patient attenuation factor for iodine-131 based on direct dose rate measurements from radioiodine therapy patients
The aim of the study was to measure the actual dose at 1 m from the patients per unit activity with the aim of providing a more accurate prediction of the dose levels around radioiodine patients in the hospital, as well as to compare our results with the literature. In this work the demonstration of a patient body tissue attenuation factor is verified by comparing the dose rates measured from the patients with those measured from the unshielded radioiodine capsules immediately after administration of the radioactivity. The normalized dose rate per unit activity is therefore proposed as an operational quantity that can be used to predict exposure rates to staff and patients’ relatives. The average dose rate measured from our patient per unit activity was 38.4±11.8 μSv/h/GBq. The calculated attenuation correction factor based on our measurements was 0.55±0.17. The calculated dose rate from a radioiodine therapy patient should normally include a factor accounting for patient body tissue attenuation and scatter. The attenuation factor is currently neglected and not applied in operational radiation protection. Realistic estimation of radiation dose levels from radioiodine therapy patients when properly performed will reduce the operational cost and optimize institutional radiation protection practice. It is recommended to include patient attenuation factors in risk assessment exercises – in particular, when accurate estimates of total effective doses to exposed individuals are required when direct measurements are not possible. The information provided about patient attenuation might benefit radiation protection specialists and regulators.
- Open Access
- 3 November 2014
- Published by SAGE Publications in Annals of the ICRP
- Vol. 44 (1_suppl) , 259-279
Trends in radiation protection of positron emission tomography/computed tomography imaging
Over the past decade, the number of positron emission tomography/computed tomography (PET/CT) imaging procedures has increased substantially. This imaging technique provides accurate functional and anatomical information, particularly for oncological applications. Separately, both PET and CT are considered as high-dose imaging modalities. With the increased use of PET/CT, one could expect an increase in radiation doses to staff and patients. As such, major efforts have been made to reduce radiation dose in PET/CT facilities. Variations in working techniques have made it difficult to compare published results. This study aimed to review the literature on proposed methods to reduce patient and staff dose in clinical PET/CT imaging. A brief overview of some published information on staff and patient doses will be analysed and presented. Recent trends regarding radiation protection in PET/CT imaging will be discussed, and practical recommendations for reducing radiation doses to staff and patients will be discussed and summarised. Generally, the CT dose component is often higher in magnitude than the dose from PET alone; as such, focusing on CT dose reduction will decrease the overall patient dose in PET/CT imaging studies. The following factors should be considered in order to reduce the patient's dose from CT alone: proper justification for ordering contrast-enhanced CT; use of automatic exposure control features; use of adaptive statistical iterative reconstruction algorithms; and optimisation of scan parameters, especially scan length. The PET dose component can be reduced by administration of lower activity to the patient, optimisation of the workflow, and appropriate use of protective devices and engineered systems. At the international level, there is wide variation in work practices among institutions. The current observed trends are such that the annual dose limits for radiation workers in PET/CT imaging are unlikely to be exceeded.
- 3 November 2014
- Published by SAGE Publications in Annals of the ICRP
- Vol. 44 (1_suppl) , 259-279
Open AccessTrends in radiation protection of positron emission tomography/computed tomography imaging
Over the past decade, the number of positron emission tomography/computed tomography (PET/CT) imaging procedures has increased substantially. This imaging technique provides accurate functional and anatomical information, particularly for oncological applications. Separately, both PET and CT are considered as high-dose imaging modalities. With the increased use of PET/CT, one could expect an increase in radiation doses to staff and patients. As such, major efforts have been made to reduce radiation dose in PET/CT facilities. Variations in working techniques have made it difficult to compare published results. This study aimed to review the literature on proposed methods to reduce patient and staff dose in clinical PET/CT imaging. A brief overview of some published information on staff and patient doses will be analysed and presented. Recent trends regarding radiation protection in PET/CT imaging will be discussed, and practical recommendations for reducing radiation doses to staff and patients will be discussed and summarised. Generally, the CT dose component is often higher in magnitude than the dose from PET alone; as such, focusing on CT dose reduction will decrease the overall patient dose in PET/CT imaging studies. The following factors should be considered in order to reduce the patient's dose from CT alone: proper justification for ordering contrast-enhanced CT; use of automatic exposure control features; use of adaptive statistical iterative reconstruction algorithms; and optimisation of scan parameters, especially scan length. The PET dose component can be reduced by administration of lower activity to the patient, optimisation of the workflow, and appropriate use of protective devices and engineered systems. At the international level, there is wide variation in work practices among institutions. The current observed trends are such that the annual dose limits for radiation workers in PET/CT imaging are unlikely to be exceeded.